SCHEMBL30115228

SCHEMBL30115228

NC(=O)c1cccnc1NC1CCOC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.47
HTT P42858 1/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 1/20 0.45
AHR P35869 1/20 0.45
RAB9A P51151 1/20 0.45
MAPK8 P45983 1/20 0.43
MAPK9 P45984 1/20 0.43
KCNH2 Q12809 6/20 0.43
ATM Q13315 3/20 0.43
RPS6KB1 P23443 2/20 0.43
ATR Q13535 1/20 0.43
AURKA O14965 1/20 0.43
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.41
SYK P43405 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3638560 0.92 MAPK1 (0.50) MAPTHTTKDM4EALDH1A1HPGD
SCHEMBL21774760 0.85 MAPT (0.45) MAPTHTTKDM4EALDH1A1HPGD
SCHEMBL4584445 0.84 MAPT (0.55) MAPTHTTKDM4EALDH1A1HPGD
Hydrochloric Acid SCHEMBL22609596 0.83 MAPT (0.54) MAPTHTTKDM4EALDH1A1HPGD
SCHEMBL3718998 0.82 MAPT (0.52) MAPTHTTKDM4EALDH1A1HPGD
SCHEMBL2718370 0.82 SYK (0.53) MAPTHTTKDM4EALDH1A1HPGD
SCHEMBL28282980 0.80 MAPK8 (0.52) MAPTHTTKDM4EALDH1A1HPGD
SCHEMBL30260224 0.80 MAPK1 (0.51) MAPTHTTKDM4EALDH1A1SMN1; SMN2
SCHEMBL1221188 0.78 TP53 (0.48) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL28079567 0.77 RPS6KB1 (0.65) MAPTHTTKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540129-B2 KIF18A inhibitors AMGEN INC. (US) 2026-02-03 US disclosed
US-20250270190-A1 KIT INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-08-28 US disclosed
US-20220372018-A1 KIF18A INHIBITORS AMGEN INC. (US) 2022-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270190-A1 KIT INHIBITORS KIT, ABL1, APC MAPT 4237/4885HTT 2531/4885KDM4E 302/4885
US-12540129-B2 KIF18A inhibitors KIF18A, KIFC1, KIF2C MAPT 645/4885HTT 3659/4885KDM4E 487/4885
US-20220372018-A1 KIF18A INHIBITORS KIF18A, KIF18B, KIF15 MAPT 315/4885HTT 2800/4885KDM4E 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.